Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol.

Koroki K, Wakatsuki M, Ogasawara S, Makishima H, Watabe T, Anzai H, Fujiya M, Sawada M, Tsuchiya T, Katayama K, Yoshino R, Izai R, Akatsuka T, Miwa C, Yonemoto T, Yumita S, Inoue M, Nakamura M, Kanogawa N, Nakamoto S, Takahashi K, Ozawa Y, Inaba Y, Kurokawa T, Isozaki T, Takahashi A, Kato J, Ohtsuka M, Ohno T, Ueno Y, Furuse J, Kudo M, Hanaoka H, Ishikawa H

Open source

DOI: 10.1136/bmjopen-2025-115731
Published: 2026 Jun 2
Container: BMJ open
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1136/bmjopen-2025-115731,
  title = {Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol.},
  author = {Koroki K and Wakatsuki M and Ogasawara S and Makishima H and Watabe T and Anzai H and Fujiya M and Sawada M and Tsuchiya T and Katayama K and Yoshino R and Izai R and Akatsuka T and Miwa C and Yonemoto T and Yumita S and Inoue M and Nakamura M and Kanogawa N and Nakamoto S and Takahashi K and Ozawa Y and Inaba Y and Kurokawa T and Isozaki T and Takahashi A and Kato J and Ohtsuka M and Ohno T and Ueno Y and Furuse J and Kudo M and Hanaoka H and Ishikawa H},
  year = {2026},
  journal = {BMJ open},
  doi = {10.1136/bmjopen-2025-115731},
  url = {https://doi.org/10.1136/bmjopen-2025-115731}
}

RIS

TY  - JOUR
TI  - Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol.
AU  - Koroki K
AU  - Wakatsuki M
AU  - Ogasawara S
AU  - Makishima H
AU  - Watabe T
AU  - Anzai H
AU  - Fujiya M
AU  - Sawada M
AU  - Tsuchiya T
AU  - Katayama K
AU  - Yoshino R
AU  - Izai R
AU  - Akatsuka T
AU  - Miwa C
AU  - Yonemoto T
AU  - Yumita S
AU  - Inoue M
AU  - Nakamura M
AU  - Kanogawa N
AU  - Nakamoto S
AU  - Takahashi K
AU  - Ozawa Y
AU  - Inaba Y
AU  - Kurokawa T
AU  - Isozaki T
AU  - Takahashi A
AU  - Kato J
AU  - Ohtsuka M
AU  - Ohno T
AU  - Ueno Y
AU  - Furuse J
AU  - Kudo M
AU  - Hanaoka H
AU  - Ishikawa H
PY  - 2026
JO  - BMJ open
DO  - 10.1136/bmjopen-2025-115731
UR  - https://doi.org/10.1136/bmjopen-2025-115731
ER  -

APA

K, K., M, W., S, O., H, M., T, W., H, A., M, F., M, S., T, T., K, K., R, Y., R, I., T, A., C, M., T, Y., S, Y., M, I., M, N., N, K., S, N., K, T., Y, O., Y, I., T, K., T, I., A, T., J, K., M, O., T, O., Y, U., J, F., M, K., H, H., & H, I. (2026). Phase Ib/II trial to evaluate the safety and efficacy of atezolizumab and bevacizumab as adjuvant therapy following carbon-ion radiotherapy in hepatocellular carcinoma (VANGUARD): study protocol.. BMJ open. https://doi.org/10.1136/bmjopen-2025-115731

Source records

pubmed · retrieved 2026-11-10T13:45:41.827Z